These are top 10 stocks traded on the Robinhood UK platform in July
Investing.com - Piper Sandler has reiterated an Overweight rating and $97.00 price target on Crinetics (NASDAQ:CRNX) ahead of the September 25th PDUFA date for PALSONIFY (paltusotine). According to InvestingPro data, the stock currently trades at $31.51, suggesting significant upside potential to analyst targets ranging from $36 to $97. The company maintains strong financial flexibility with more cash than debt on its balance sheet.
The firm based its assessment on feedback from a leading endocrinologist specializing in pituitary tumors who treats approximately 200 acromegaly patients at a major referral center. The specialist highlighted significant challenges with current injectable somatostatin analogs, estimating less than 50% real-world compliance.
The medical expert expressed enthusiasm for PALSONIFY, describing the Phase 3 PATHFNDR-1/-2 trials as a "remarkable success" supporting probability of success for broad acromegaly approval. The specialist plans to offer PALSONIFY immediately to almost all patients, except approximately 5-10% who need further tumor shrinkage.
Piper Sandler noted the endocrinologist believes the once-daily oral medication would eventually become the cornerstone of acromegaly treatment due to its simplicity and safety profile. The specialist was also impressed with atumelnant’s Phase 1b/2a Cushing’s disease data.
Piper Sandler identified Crinetics as one of its top second-half 2025 picks, citing potential upside into PALSONIFY’s approval and launch, along with what it describes as a catalyst-rich outlook for the next 18+ months. With a current market capitalization of $2.96 billion and a robust current ratio of 22.53, InvestingPro data reveals the company’s strong liquidity position. Discover more comprehensive insights and 8 additional ProTips for CRNX with an InvestingPro subscription.
In other recent news, Crinetics Pharmaceuticals has been the subject of multiple analyst reviews and presentations. The company has received a Buy rating from both H.C. Wainwright and Jones Trading, with price targets set at $81 and $71, respectively. These ratings come after the ENDO 2025 conference, where Crinetics presented promising data on its lead drug candidate, paltusotine, for acromegaly treatment. The data showed sustained biochemical control and reduced symptom burden in long-term studies, which are expected to support the drug’s commercial uptake. JMP Securities also reiterated a Market Outperform rating with a $90 price target, citing strong long-term safety and efficacy data for paltusotine. Meanwhile, Goldman Sachs initiated coverage with a Neutral rating and a $36 price target, citing uncertainties around the upcoming launch of paltusotine and its addressable market size. Additionally, Crinetics is advancing its pipeline with atumelnant for congenital adrenal hyperplasia (CAH), with pivotal studies planned for 2025. The company is also preparing to present Phase 2 data for atumelnant, which has shown promising results in reducing key biomarkers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.